According to Stemtech, a public direct selling company, press release:
Stemtech Corporation (“Stemtech”) (OTCQB:STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that the Company has been approved for uplisting to the OTCQB® Venture Market (the OTCQB®), which is operated by OTC Markets Group, Inc.
Charles S. Arnold, Chairman and CEO of Stemtech said:
“This is a significant milestone in the history of our Company. We are pleased that OTC Markets approved our uplisting to OTCQB®, which we believe will meaningfully enhance our visibility with high quality investors.
Our uplisting demonstrates that we are committed to the disclosure requirements that OTC Markets mandates for this tier, including financial reporting, annual verification and management certification of information that is relevant to existing and potential shareholders.
Additionally, we will be participating in the OTC Markets Virtual Investor Conferences.”
Mr. Arnold continued,
“Our uplisting is a positive first step towards raising our profile in the investment community and in our industry. Recently, we were honored to receive recognition for the momentum we are achieving in the Direct Selling industry.
As of April 28th, 2022 Stemtech was recognized as a company on the move on the Business For Home Momentum Rank list.